NCT06771843 Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments
| NCT ID | NCT06771843 |
| Status | Recruiting |
| Phase | — |
| Sponsor | San Diego State University |
| Condition | HIV Antiretroviral Therapy (ART) Adherence |
| Study Type | INTERVENTIONAL |
| Enrollment | 716 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 716 participants in total. It began in 2025-06-16 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators developed the Kisoboka ("It is possible") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in "risk environments" such as fishing communities through reductions in hazardous alcohol use, improved adherence to HIV medications and achieving undetectable HIV viral loads. Social and structural determinants unique to fishing communities interact to create a risk environment where hazardous drinking impedes adherence to HIV medications among men living with HIV, including prevalent social norms of drinking, drinking as a way of experiencing "reward" and connecting with others (e.g. in the context of transactional sex), stressful work conditions, a "live for today" outlook, and a cash-based economy with no traditional savings infrastructure leading to ease of daily expenditure on drinking and sex work. These social and environmental conditions result in high levels of alcohol misuse and HIV risk, poor HIV outcomes, and exacerbation of HIV-associated wellness comorbidities such as poor mental and subjective physical health and food insecurity. The goal of this study is to learn if the intervention called Kisoboka works to help men in fishing communities reduce hazardous alcohol use, be better able to take the participants HIV medication as prescribed, and have undetectable HIV viral loads. The investigators will compare the Kisoboka intervention to a brief alcohol screening, adherence counseling, and referrals, and to components of the Kisoboka intervention. Participants will attend intervention counseling sessions according to the study arm to which the participants are randomly assigned. The number of sessions ranges from 1 to 6 over 1 to 16 weeks and are individual only or both individual and group sessions.
Eligibility Criteria
Inclusion Criteria: 1. living with HIV; 2. residing in a fishing community (on most days/nights); 3. AUDIT-C positive (≥4) indicating potential hazardous drinking; 4. \>6 months since initial antiretroviral treatment (ART) initiation; 5. not planning to move from the area within the next 6 months; 6. have their own mobile phone and can be reached via phone. 7. an indicator of potential suboptimal treatment as prevention (TasP) either: (i) last HIV viral load test (within 6 months) was detectable (\>20) or (ii) last viral load test between 6 and 13 months ago was detectable (\>20) and reports missing ≥2 ART doses in the past 2 weeks or (iii) a lack of viral load test results for the prior 13 months in clinic records and reports missing ≥2 ART doses in the past 2 weeks; Exclusion Criteria: 1. visibly intoxicated at enrollment (eligible to enroll when not intoxicated); 2. does not speak Luganda or English; 3. currently receiving a majority of work payments via mobile money/digital payments; 4. participated in the Kisoboka pilot RCT; 5. unable to read basic Luganda or English
Contact & Investigator
Susan M Kiene, PhD, MPH
PRINCIPAL INVESTIGATOR
San Diego State University
Frequently Asked Questions
Who can join the NCT06771843 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying HIV Antiretroviral Therapy (ART) Adherence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06771843 currently recruiting?
Yes, NCT06771843 is actively recruiting participants. Contact the research team at jmatovu@musph.ac.ug for enrollment information.
Where is the NCT06771843 trial being conducted?
This trial is being conducted at Kampala, Uganda.
Who is sponsoring the NCT06771843 clinical trial?
NCT06771843 is sponsored by San Diego State University. The principal investigator is Susan M Kiene, PhD, MPH at San Diego State University. The trial plans to enroll 716 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.